Traditional neuropathologic methods have provided only limited insight into the central nervous system abnormalities underlying Tourette syndrome. In the past 20 years, investigators have turned increasingly to in vivo neuroimaging approaches to localize, quantify, and characterize neuroanatomic, functional, and neurochemical distinctions in living subjects with Tourette syndrome. Research methods have included aggregate measures of cerebral energy metabolism, assessments of cerebral structure and size, and highly specific assessments of neurochemical markers of select neurons and synapses. Although the available data have important limitations, an encouraging convergence of findings implicates abnormal function in the Tourette syndrome striatum and in associated limbic and frontal cortical systems. (J Child Neurol 2006;21:672—677; DOI 10.2310/7010.2006.00162).
Get full access to this article
View all access options for this article.
References
1.
Richardson EP : Neuropathological studies of Tourette syndrome . Adv Neurol1982;35:83—87.
2.
Swerdlow NR, Young AB: Neuropathology in Tourette syndrome: An update, in Goetz CG, Jankovic J (eds): Tourette Syndrome. Philadelphia, Lippincott Williams & Wilkins, 2001, 151—161.
3.
Haber SN, Kowall NW, Vonsattel JP, et al: Gilles de la Tourette syndrome: A post-mortem neuropathological and immunohistochemical study. J Neurol Sci1986;75:225—241.
4.
Haber SN, Wolfer D.: Basal ganglia peptidergic staining in Tourette syndrome: A follow-up study . Adv Neurol1992;48:145— 150.
5.
Kalanithi Psa , Zheng W., Kataoka Y., et al:Altered parvalbuminpositive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci U S A 2005;102:13307— 13312.
6.
Toga AW, Mazziotta JC(eds): Brain Mapping. The Methods, 2nd ed. San Diego, Academic Press, 2002.
7.
Agranoff BW, Frey KA: A regional metabolic contrast method for the study of brain pathology. Ann Neurol1984;15(Suppl):S93—S97.
8.
Frey KA: Neurochemical systems, in Valk PE, Bailey DL, Townsend DW, Maisey MN (eds): Positron Emission Tomography. Basic Science and Clinical Practice. London, Springer-Verlag, 2003, 309—327.
9.
Thompson PM, Cannon TD, Narr KL, et al: Genetic influences on brain structure. Nat Neurosci2001;4:1253—1258.
10.
Braun AR, Stoetter B., Randolph C., et al: The functional neuroanatomy of Tourette's syndrome: An FDG-PET study. I: Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology1993;9:277— 291.
11.
Braun AR, Randolph C., Stoetter B., et al: The functional neuroanatomy of Tourette's syndrome: An FDG-PET study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology1995;13:151—168.
12.
Eidelberg D., Moeller JR, Antonini A., et al: The metabolic anatomy of Tourette's syndrome. Neurology1997;48:927—934.
13.
Jeffries KJ , Schooler C., Schoenbach C., et al: The functional neuroanatomy of Tourette's syndrome: An FDG PET study III: Functional coupling of regional cerebral metabolic rates. Neuropsychoparmacology2002;27:92—104.
14.
Peterson BS , Skudlarski P., Anderson AW, et al: A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch Gen Psychiatry1998;55:326—333.
15.
Stern E., Silbersweig DA, Chee KY, et al: A functional neuroanatomy of tics in Tourette syndrome. Arch Gen Psychiatry2000;57:741—748.
16.
Biswal B., Ulmer JL, Krippendorfer RL, et al: Abnormal cerebral activation associated with a motor task in Tourette syndrome. AJNR Am J Neuroradiol1998 ;19:1509—1512.
17.
Jankovic J. : Tourette's syndrome. N Engl J Med2001;345:1184— 1192.
18.
Robertson MM : Tourette syndrome, associated conditions and the complexities of treatment. Brain2000;123:425—462.
19.
Singer HS, Butler IJ, Tune LE, et al: Dopaminergic dysfunction in Tourette syndrome. Ann Neurol1982;12:361—366.
20.
Anderson GM , Pollak ES, Chatterje D., et al: Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol1992;58:123—133.
21.
Singer HS, Hahn IS, Moran TH: Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette syndrome. Ann Neurol199 1;30:558-562.
22.
Wolf SS, Jones DW, Knable MB, et al: Tourette syndrome: Prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science1996;273:1225— 1227.
23.
Wong DF, Singer HS, Brandt J., et al: D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med1997;38:1243—1247.
24.
Muller-Vahl KR, Berding G., Kolbe H., et al: Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurol Scand2000;101:165—171.
25.
Malison RT, McDougle CJ, van Dyck CH, et al: [123I]β-CIT SPECT imaging of striatal dopamine transporter sites in Tourette's disorder. Am J Psychiatry1995;152:1359—1361.
26.
Stamenkovic M., Schindler SD, Asenbaum S., et al: No change in striatal dopamine re-uptake site density in psychotropic drug naïve and in currently treated Tourette's disorder patients: A [123I]-β-CIT SPECT study. Eur Neuropsychopharmacol2001;11: 69—74.
27.
Muller-Vahl KR, Berding G., Brucke T., et al: Dopamine transporter binding in Gilles de la Tourette syndrome. JNeurol2000;247:514-520.
28.
Heinz A., Knable MB, Wolf SS, et al: Tourette's syndrome: [123I]βCIT SPECT correlated of vocal tic severity. Neurology1998;51: 1069—1074.
29.
Serra-Mestres J., Ring HA, Costa DC, et al: Dopamine transporter binding in Gilles de la Tourette syndrome: A [123I]FP-CIT/SPECT study. Acta Psychiatr Scand2004;109:140—146.
30.
Cheon KA, Ryu YH, Namkoong K., et al: Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Res2004;130:85—95.
31.
Turjanksi N. , Sawle GV, Playford ED, et al: PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry1994;57:688—692.
32.
Ernst M., Zametkin AJ, Jons PH, et al: High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry1999;38:86—94.
33.
Vander Borght TM, Kilbourn MR, Desmond TJ, et al: The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol1996;294:577—583.
34.
Vander Borght TM, Sima Aaf, Kilbourn MR, et al: [3H]Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience1995; 68:955—962.
35.
Meyer P., Bohnen NI, Minoshima S., et al: Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology1999;53:371—374.
36.
Albin RL, Koeppe RA, Bohnen NI, et al: Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology2003;61:310—315.
37.
Singer HS, Szymanski S., Giuliano J., et al: Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry2002;159:1329—1336.
38.
Peterson B. , Riddle MA, Cohen DJ, et al: Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images. Neurology1993;43:941—949.
39.
Singer HS, Reiss AL, Brown JE, et al: Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. Neurology1993;43:950—956.
40.
Moriarty J. , Varma AR, Stevens J., et al: A volumetric MRI study of Gilles de la Tourette's syndrome. Neurology1997;49:410—415.
41.
Zimmerman AM , Abrams MT, Giuliano JD, et al: Subcortical volumes in girls with Tourette syndrome. Neurology2000;54: 2224—2229.
42.
Kates WR, Frederikse M., Mostofsky SH, et al: MRI parcellation of the frontal lobe in boys with attention deficit hyperactivity disorder or Tourette syndrome. Psychiatr Res Neuroimaging2002;116:63—81.
43.
Hong KE, Ock SM, Kang MH, et al: The segmented regional volumes of the cerebrum and cerebellum in boys with Tourette syndrome. J Korean Med Sci2002; 17:530-536.
44.
Hyde TM, Stacey ME, Coppola R., et al: Cerebral morphometric abnormalities in Tourette's syndrome: A quantitative MRI study of monozygotic twins. Neurology1995;45:1176—1182.
45.
Baumgardner TL, Singer HS, Denckla MB, et al: Corpus callosum morphology in children with Tourette syndrome and attention deficit hyperactivity disorder. Neurology1996;47:477—482.
46.
Fredericksen KA, Cutting LE, Kates WR, et al: Disproportionate increases of white matter in right frontal lobe in Tourette syndrome. Neurology2002;58:85—89.
47.
Peterson BS , Staib L., Scahill L., et al: Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry2001;58:427—440.
48.
Peterson BS , Thomas P., Kane MJ, et al: Basal ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry2003;60:415—424.
